MedPath

SUN PHARMACEUTICAL INDUSTRIES LIMITED

🇮🇳India
Ownership
-
Employees
-
Market Cap
-
Website

Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus

Phase 3
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Placebo
Drug: SPIL1033
First Posted Date
2011-08-01
Last Posted Date
2020-08-11
Lead Sponsor
Sun Pharmaceutical Industries Limited
Target Recruit Count
360
Registration Number
NCT01406717
Locations
🇮🇳

SPIL Site 26, Hyderabad, Andhra Pradesh, India

🇮🇳

SPIL Site 2, Ahmedabad, Gujrat, India

🇮🇳

SPIL Site 7, Surat, Gujrat, India

and more 31 locations

Aqueous Humor Concentration of InSite Vision (ISV) 303 (Bromfenac in DuraSite) to Bromday Once Daily (QD) Prior to Cataract Surgery

Phase 2
Completed
Conditions
Cataract
Interventions
Drug: ISV-303
Drug: Bromdayâ„¢
First Posted Date
2011-07-04
Last Posted Date
2021-11-19
Lead Sponsor
Sun Pharmaceutical Industries Limited
Target Recruit Count
60
Registration Number
NCT01387464

Prospective Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine

Phase 4
Withdrawn
Conditions
Stomatitis
Oral Mucositis
Interventions
First Posted Date
2011-02-02
Last Posted Date
2021-11-17
Lead Sponsor
Sun Pharmaceutical Industries Limited
Registration Number
NCT01288625

Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers

Phase 1
Completed
Conditions
Ocular Inflammation
Interventions
Drug: ISV-303
Drug: DuraSite Vehicle
Drug: Xibromâ„¢
First Posted Date
2010-08-30
Last Posted Date
2021-11-19
Lead Sponsor
Sun Pharmaceutical Industries Limited
Target Recruit Count
169
Registration Number
NCT01190878

Letrozole vs. Clomiphene Citrate in Patients With Anovulatory Infertility

Phase 3
Completed
Conditions
Infertility
Interventions
First Posted Date
2008-02-07
Last Posted Date
2008-02-07
Lead Sponsor
Sun Pharmaceutical Industries Limited
Target Recruit Count
55
Registration Number
NCT00610077
Locations
🇮🇳

IVF Centre, Chembur,, Mumbai-, Maharashtra, India

Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis

Phase 3
Completed
Conditions
Blepharoconjunctivitis
Interventions
First Posted Date
2007-12-21
Last Posted Date
2021-11-19
Lead Sponsor
Sun Pharmaceutical Industries Limited
Target Recruit Count
417
Registration Number
NCT00578955
© Copyright 2025. All Rights Reserved by MedPath